Literature DB >> 21454012

CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells.

Massod Rahimi1, Theodore A Toth, Careen K Tang.   

Abstract

Our previous report has shown that the constitutively activated EGFR variant, EGFRvIII, up-regulates the pro-metastatic chemokine receptor CXCR4 in breast cancer cells. Here we evaluated the biological effect and cell signaling effects of silencing CXCR4 expression in EGFRvIII-expressing breast cancer cells. Short hairpin RNA (shRNA)-mediated suppression of CXCR4 expression significantly reduced the invasive potential and proliferation of EGFRvIII-expressing breast cancer cells. These cells exhibited a reduction of EGFRvIII activity and protein expression due to increased protein degradation and altered protein trafficking. In conclusion, suppression of CXCR4 inhibits EGFRvIII-mediated breast cancer cell invasion and proliferation.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454012      PMCID: PMC3100082          DOI: 10.1016/j.canlet.2011.02.024

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  31 in total

1.  Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII.

Authors:  Sylvie J Lavictoire; Doris A E Parolin; Alex C Klimowicz; John F Kelly; Ian A J Lorimer
Journal:  J Biol Chem       Date:  2002-12-05       Impact factor: 5.157

2.  Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.

Authors:  C K Tang; X Q Gong; D K Moscatello; A J Wong; M E Lippman
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

3.  Silencing of CXCR4 blocks breast cancer metastasis.

Authors:  Zhongxing Liang; Younghyoun Yoon; John Votaw; Mark M Goodman; Larry Williams; Hyunsuk Shim
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

4.  T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.

Authors:  Hirokazu Tamamura; Akira Hori; Naoyuki Kanzaki; Kenichi Hiramatsu; Makiko Mizumoto; Hideki Nakashima; Naoki Yamamoto; Akira Otaka; Nobutaka Fujii
Journal:  FEBS Lett       Date:  2003-08-28       Impact factor: 4.124

5.  Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways.

Authors:  Hong Yu; Xiaoqi Gong; Xunyi Luo; Wei Han; Ge Hong; Baljit Singh; Careen K Tang
Journal:  Cancer Biol Ther       Date:  2008-11-24       Impact factor: 4.742

6.  Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance.

Authors:  Guido Lammering; Kristoffer Valerie; Peck-Sun Lin; Theodore H Hewit; Rupert K Schmidt-Ullrich
Journal:  Radiother Oncol       Date:  2004-09       Impact factor: 6.280

7.  CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo.

Authors:  Natalia Lapteva; An-Gang Yang; Denise E Sanders; Randall W Strube; Si-Yi Chen
Journal:  Cancer Gene Ther       Date:  2005-01       Impact factor: 5.987

8.  Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

Authors:  Zhongxing Liang; Tao Wu; Hong Lou; Xiwen Yu; Russell S Taichman; Stephen K Lau; Shuming Nie; Jay Umbreit; Hyunsuk Shim
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

9.  Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro.

Authors:  Yangchao Chen; George Stamatoyannopoulos; Chao-Zhong Song
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

10.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

Authors:  Yan M Li; Yong Pan; Yongkun Wei; Xiaoyun Cheng; Binhua P Zhou; Ming Tan; Xiaoyan Zhou; Weiya Xia; Gabriel N Hortobagyi; Dihua Yu; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

View more
  7 in total

1.  CoCl2 increases the expression of hypoxic markers HIF-1α, VEGF and CXCR4 in breast cancer MCF-7 cells.

Authors:  Qing Li; Rong Ma; Mei Zhang
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

Review 2.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

3.  EGFR soluble isoforms and their transcripts are expressed in meningiomas.

Authors:  Angélique Guillaudeau; Karine Durand; Barbara Bessette; Alain Chaunavel; Isabelle Pommepuy; Fabrice Projetti; Sandrine Robert; François Caire; Hélène Rabinovitch-Chable; François Labrousse
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

4.  Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.

Authors:  Wen Xu; Yanyu Bi; Jiqin Zhang; Juan Kong; Hua Jiang; Mi Tian; Kesang Li; Biao Wang; Cheng Chen; Fei Song; Xiaorong Pan; Bizhi Shi; Xianming Kong; Jianren Gu; Xiumei Cai; Zonghai Li
Journal:  Oncotarget       Date:  2015-11-17

5.  CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells.

Authors:  Min Zhang; Lisha Qiu; Yanyan Zhang; Dongsheng Xu; Jialin C Zheng; Li Jiang
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

6.  EGFR expression is associated with cytoplasmic staining of CXCR4 and predicts poor prognosis in triple-negative breast carcinomas.

Authors:  Rong-Hui Li; Wen-He Huang; Jun-Dong Wu; Cai-Wen Du; Guo-Jun Zhang
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

7.  EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression.

Authors:  Xiaoying Luo; Hailong Xie; Xiaolan Long; Min Zhou; Zhibin Xu; Bizhi Shi; Hua Jiang; Zonghai Li
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.